Teva gets OK for P&G copycat

Teva Pharmaceutical Industries got the FDA's thumbs up for its version of the Procter & Gamble drug Actonel. The osteoporosis remedy has annual U.S. sales of $1 billion, and Teva will get first-out-of-the-gate marketing exclusivity for 180 days.

Not that Teva will sell the drug yet. It and P&G have been in a dispute over Actonel's patent. The case went to trial in late 2006 but has dragged on, with no decision reached. As part of that litigation, Teva agreed to give P&G 30 days notice before it markets Actonel; that notice hasn't yet been given.

- see Teva's press release
- read the report from the Cincinnati Business Journal

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.